ArticleResearch in pharmaceutical sciences2026
Aptamer targeting proprotein convertase subtilisin/kexin type 9:
Article in Research in pharmaceutical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a key therapeutic target for lowering low-density lipoprotein cholesterol (LDL-C). This study aimed to evaluate the LDL-C-lowering efficacy of a PCSK9-targeting aptamer (AP-1) in a hypercholesterolemic rat model. Experimental approach: Wistar male rats (n = 48) were divided into 8 groups (n = 6): normal control, negative control, positive control receiving atorvastatin (4 mg/kg body weight) plus ezetimibe (1 mg/kg BW), and a PBS vehicle group. Experimental groups received the aptamer intraperitoneally at 1, 3, and 8 μM;, and one group received 3 μM; aptamer combined with atorvastatin (4 mg/kg BW). Hypercholesterolemia was induced for over 90 days, followed by a 4-week treatment period. Serum lipid parameters, including triglycerides (TG), total cholesterol (T-Chol), LDL-C, and atherogenic indices, were assessed. Findings/Results: TG, 143.2 ± 16.44 vs. 109 ± 23.05 mg/dL; T-Chol, 88 ± 3.11 vs. 80 ± 7.16 mg/dL, and LDL-C, 19.4 ± 1.12 vs. 14.5 ± 1.56 mg/dL, levels were significantly increased in the hypercholesterolemic rat model compared to the normal group. Treatment with the 3 μM; aptamer produced the most pronounced lipidlowering effects, significantly reducing TG, 95.2 ± 8.76 vs. 143.2 ± 16.44 mg/dL; T-Chol, 61.2 ± 5.11 vs. 88 ± 3.11 mg/dL, and LDL-C, 11.4 ± 0.75 vs. 19.4 ± 1.12 compared to the hypercholesterolemic control group. Furthermore, the atherogenic index of plasma, remnant cholesterol, and Castelli risk index-II were reduced significantly. Conclusion and implications: AP-1 aptamer-mediated PCSK9 inhibition significantly improved lipid profiles and atherogenic indices, supporting aptamers as a viable alternative to monoclonal antibody-based PCSK9 inhibition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.